Landmark Project - Prof David Dexter and Prof Michael Johnson
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
Landmark is a ground-breaking research programme aimed at accelerating the search for new treatments by applying cutting edge techniques to gain a new level of insight at cellular level into the changes Parkinson's causes in the brain. Principal investigator Professor Michael Johnson from Imperial College London explains the need across the global research community for the new high quality datasets his team will produce.
The project will use tissue samples from the Parkinson's UK Brain Bank, which was set up 22 years ago as a result of the remarkable foresight of Professor David Dexter, who is now the charity's Director of Research. He explains what it was like to see his vision come to fruition when Landmark was launched.
The three year research programme brings together a Parkinson's UK led consortium of four major pharmaceutical companies - GSK, Novartis, Roche, and UCB, plus Imperial College London, which was made possible with £4m of funding from the Gatsby charitable foundation.